NICE put on defensive as ruling on Relenza ends in row over 'leaks'

By Tash Shifrin1999-10-07T00:00:00

The National Institute for Clinical Excellence has defended its handling of the fast-track appraisal of Relenza, despite concern about the way news that the anti-flu drug had been turned down for NHS prescription this winter emerged.

You need to be a subscriber to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All HSJ news by sector, topic & region
Breaking News announcements
App for mobile and offline reading
Comment and Daily Insights newsletters
Regional roundup newsletters
Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
10 expert briefings every fortnight (Premium only)

to HSJ

Already a subscriber? Sign into your account here